Sachs 9th Annual Immuno-Oncology Innovation Forum presentation

Brisbane, 2 June 2023

QBiotics Group Limited (QBiotics) is pleased to share a copy of the presentation to be delivered at the Sachs 9th Annual Immuno-Oncology Innovation Forum for Business Development, Licensing and Investment on 2 June 2023 in Chicago, USA.

The forum brings together leaders from cancer research institutes, patient advocacy groups, pharma, biotech, and Wall Street to facilitate partnering, funding and investment. It is scheduled the day before the ASCO conference starts. The programme includes high-level keynotes and panel discussions covering the latest trends in Pharma and Biotech BD, scientific and clinical innovation and investment. Additionally, there will be pre-arranged in-person and virtual meetings, live and on demand company showcases.

In the presentation Richard Godfrey, representing QBiotics in Business Development, Licensing and Partnerships, will provide an update on the Company’s human and veterinary programmes in oncology and wound healing. The presentations will include recent Phase I safety and efficacy data with tigilanol tiglate (TT) in cancer patients, and details of two ongoing Phase II studies in later stage patients with Head and Neck cancer and Soft Tissue Sarcoma, being treated with TT.

Presentation details

Conference: Sachs 9th Annual Immuno-Oncology Innovation Forum for Business Development, Licensing and Investment at the Waldorf Astoria Chicago Hotel, USA
Date: 2 June 2023
Time/s: Richard Godfrey will present in Track A which commences at 11:40 AM Central Daylight Time (GMT-5).
Meetings: Any potential partners or investors interested in engaging around QBiotics and its programmes are invited to contact the Company directly or via the one-on-one conference partnering systems.
Virtual copy: Recorded sessions will also be added to the event portal as available on demand during the virtual week, which takes place from 13 – 15 June EDT.

You can download the presentation and more information on the conference is available via the following link:


Dr Victoria Gordon, CEO & Managing Director, QBIOTICS GROUP or

Richard Godfrey Business Development, Licensing and Partnering

JANE LOWE, IR DEPARTMENT or +61 411 117 774



QBiotics is an unlisted public Australian life sciences company that discovers and develops pharmaceuticals derived from nature to address unmet medical needs in humans and companion animals. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.

QBiotics’ business model is to develop products that have applications in both veterinary and human markets. Success in the veterinary programme validates QBiotics technology and de-risks human development while having the potential to generate early revenue.

QBiotics’ lead oncology product, tigilanol tiglate, is a small molecule targeting a range of solid tumours and is currently in human clinical Phase II development. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA®, in the USA, Europe, the UK and Australia.

QBiotics’ lead wound healing product is a small molecule targeting a range of wounds including chronic and acute wounds and burns. Preparation is in progress for a first-in-human Phase I/IIa clinical trial in patients with venous leg ulcers.